Chapter 35. Current Areas of Controversy in the Treatment of Patients with Newly Diagnosed Acute Promyelocytic Leukemia

  1. Mark A. Crowther MD, MSc, FRCPC Professor Division Director2,3,
  2. Jeff Ginsberg MD, FRCPC Professor4,
  3. Holger J. Schünemann MD, PhD, MSc, FACP, FCCP Professor5,6,
  4. Ralph M. Meyer MD, FRCPC Director Professor7,8 and
  5. Richard Lottenberg MD, FACP Professor9
  1. Martin S. Tallman MD and
  2. Syed A. Abutalib MD

Published Online: 4 FEB 2009

DOI: 10.1002/9781444300857.ch35

Evidence-Based Hematology

Evidence-Based Hematology

How to Cite

Tallman, M. S. and Abutalib, S. A. (2008) Current Areas of Controversy in the Treatment of Patients with Newly Diagnosed Acute Promyelocytic Leukemia, in Evidence-Based Hematology (eds M. A. Crowther, J. Ginsberg, H. J. Schünemann, R. M. Meyer and R. Lottenberg), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444300857.ch35

Editor Information

  1. 2

    Division of Hematology, McMaster University, Hamilton, Ontario, Canada

  2. 3

    St. Joseph's Hospital, Hamilton, Ontario, Canada

  3. 4

    Department of Medicine, McMaster University, Hamilton, Canada

  4. 5

    CLARITY Research Group, Department of Epidemiology, Italian National Cancer Institute Regina Elena, Rome, Italy

  5. 6

    McMaster University, Hamilton, Canada

  6. 7

    National Cancer Institute of Canada, Clinical Trials Group, Edith Eisenhauer Chair in Clinical Cancer Research, Queen's University, Kingston, Ontario, Canada

  7. 8

    Departments of Oncology and Medicine, Queen's University, Kingston, Ontario, Canada

  8. 9

    Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA

Author Information

  1. Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, USA

Publication History

  1. Published Online: 4 FEB 2009
  2. Published Print: 27 JUN 2008

ISBN Information

Print ISBN: 9781405157476

Online ISBN: 9781444300857



  • acute promyelocytic leukemia (APL);
  • malignant hematologic disorders;
  • American Society of Clinical Oncology (ASCO);
  • American Society of Hematology (ASH);
  • arsenic trioxide treatment in patients with relapsed and refractory APL;
  • treatment of high-risk APL;
  • maintenance therapy for patients with APL


This chapter contains sections titled:

  • Introduction

  • Literature search and inclusion

  • Is ara-C required in induction and/or consolidation in patients with newly diagnosed APL?

  • Can newly diagnosed patients be treated with ATRA and ATO?

  • What is the best treatment for patients with high-risk APL?

  • Is maintenance therapy needed for all patients with APL?

  • Recommendation

  • References